Antiviral Agents Against Ebola Virus

Ebola virus disease (EVD) is caused by a negative-sense single-stranded RNA virus of the family Filoviridae. The 2013–2016 West Africa epidemic — the largest in history — killed over 11,000 people and exposed the near-total absence of approved antiviral therapies. The subsequent 2018–2020 DRC outbreak further underscored the urgency.

The EBOV life cycle presents multiple druggable targets: (1) host membrane fusion during entry, (2) viral RNA-dependent RNA polymerase (RdRp) during genome replication, (3) VP35 and VP24 — IFN antagonists — and (4) VP40 matrix protein during virion budding. Drug repurposing strategies have dominated early-stage research due to the known safety profiles of existing compounds.

Ebola Virus Life Cycle — Key Drug Targets

• Attachment & Entry: GP-mediated fusion with the endosomal membrane after NPC1 receptor binding — targeted by TPC inhibitors, antiestrogens, and ZMapp
• Replication: RNA-dependent RNA polymerase (RdRp) complex — targeted by nucleoside/nucleotide analogs (favipiravir, remdesivir, BCX4430)
• IFN Evasion: VP35 (blocks IRF-3/7) and VP24 (blocks STAT1 nuclear import) — immunomodulatory targets
• Budding: VP40 matrix protein interacts with host Abl/Src kinases — targeted by imatinib and nilotinib

Ebola virus enters host cells via macropinocytosis. The viral glycoprotein (GP) is cleaved by cathepsins B and L in the endosome, exposing the receptor-binding domain that interacts with NPC1 (Niemann-Pick C1 protein). Membrane fusion then requires Two-Pore Channel (TPC) activity. All these steps are targetable.

TPC Inhibitors

• Bisbenzylisoquinoline alkaloid; blocks two-pore channels (TPC1/TPC2) on endolysosomal membranes
• EC50 = 55 nM in cell-based assays — exceptionally potent entry blocker
• Inhibits calcium-dependent fusion step required for GP-membrane merger
• Also active against Marburg virus and other filoviruses

Selective Estrogen Receptor Modulators (SERMs) — Repurposed

• Toremifene (EC50 ≈ 0.56 μM): Binds EBOV GP, disrupts GP–NPC1 interaction at the endosomal stage; 50% mouse survival in lethal challenge models; acts independently of ER — antiviral effect is ER-independent
• Clomiphene: Targets NPC1 receptor directly; 90% mouse survival in challenge models; blocks cathepsin-processed GP from engaging NPC1; also inhibits lysosomal cholesterol transport needed for viral escape
• Both identified via high-throughput screening of FDA-approved drug libraries — strong repurposing candidates

Antihistamines & Other Cationic Amphiphiles

• Multiple FDA-approved antihistamines (chlorpheniramine, promethazine) show modest anti-EBOV activity by altering endosomal pH and disrupting GP-mediated fusion
• Chloroquine and amiodarone: block endosomal acidification; limited in vivo efficacy despite promising in vitro data

Passive immunotherapy using GP-targeting monoclonal antibodies (mAbs) represents the most clinically advanced anti-EBOV strategy. Three antibody cocktails have received prominent attention:

ZMapp

• A combination of three chimeric (mouse/human) mAbs: c13C6, c2G4, c4G7 — all targeting the EBOV glycoprotein
• 100% survival in rhesus macaques when given up to 5 days post-infection (the latest post-exposure treatment showing full protection)
• Produced in Nicotiana benthamiana (tobacco plants) using the ZMapp manufacturing platform — rapid scale-up possible
• Used under compassionate use in the 2014–2016 West Africa outbreak; randomized controlled trial (PREVAIL II) showed trend toward improved survival but was underpowered
• Mechanism: c13C6 binds the glycan cap; c2G4 and c4G7 bind the GP base/fusion loop — together they block attachment, fusion, and trigger ADCC

MB-003

• Three plant-produced mAbs: 13C6, 6D8, 13F6 — earlier generation cocktail derived from ZMAb
• 75% human survival reported in a 2014 New England Journal of Medicine case series of compassionate use patients
• Partial protection: effective when given early; NHP studies showed 43% survival at 4–5 days post-infection

ZMAb

• Murine mAb cocktail (c1H3, c2G4, c4G7); precursor to ZMapp
• 100% NHP survival when given within 24 hours post-infection; reduced efficacy at later time points (50% at 48h)
• Fully replaced by ZMapp in clinical development due to chimerization for human use

Clinical note: In the PALM trial (DRC, 2018–2019), two GP-targeting mAbs — mAb114 (Ansuvimab) and REGN-EB3 (Inmazeb — atoltivimab/maftivimab/odesivimab) — showed mortality rates of ~29% vs. ~49% for ZMapp, leading the FDA to approve REGN-EB3 and mAb114 in 2020. The Fanunza 2018 review predates these trial results but provides the mechanistic foundation.

The EBOV RNA-dependent RNA polymerase (RdRp) complex — composed of L protein, VP35, and VP30 — is an attractive target since it has no mammalian counterpart. Nucleoside analog prodrugs that are incorporated into nascent viral RNA and cause chain termination or error catastrophe are the primary approach.

Remdesivir (GS-5734) — Most Promising

• Monophosphoramidate prodrug of a 1'-cyano-modified adenosine nucleotide analog; developed by Gilead Sciences
• Mimics adenosine; incorporated into the nascent RNA strand; causes delayed chain termination after 3 more nucleotide incorporations, evading RNA proofreading mechanisms
• 100% survival in rhesus macaque NHP model — the most impressive single-agent result reported for any anti-EBOV drug at time of publication
• 5 out of 7 macaques protected when treatment started 3 days post-infection — demonstrated significant post-exposure window
• IV formulation used in clinical setting; oral formulation under development
• Active against Marburg, SARS, MERS, and RSV — broad-spectrum RNA antiviral; later repurposed for COVID-19 (FDA-approved under EUA 2020, full approval 2022)
• Mechanism confirmed: preferentially inhibits EBOV RdRp (L protein) over human RNA polymerases at therapeutic concentrations

Favipiravir (T-705)

• Prodrug activated intracellularly to favipiravir-RTP (ribose triphosphate); inhibits RNA-dependent RNA polymerase by acting as a purine nucleotide mimic
• Mechanism: causes lethal mutagenesis — increased error rate in viral RNA replication leads to non-viable progeny
• Mouse models: significant protection; effective in Guinea pig model of EVD
• Phase II trial during 2014 Guinea epidemic (JIKI trial): mixed results — reduced mortality in patients with low–moderate viral loads; no benefit in very high viral load (Ct < 20) patients; possibly effective if initiated early
• Major limitation: requires very high oral doses (loading dose 6,000 mg → 2,400 mg/day) — practical challenge in outbreak settings
• Also approved in Japan for novel influenza; studied for COVID-19

BCX4430 (Galidesivir)

• Broad-spectrum adenosine nucleoside analog developed by BioCryst Pharmaceuticals
• Acts as a non-obligate RNA chain terminator when incorporated by RdRp
• 100% NHP survival in Marburg virus model; significant EBOV protection in mice and Guinea pigs
• Phase I human safety trial (NCT02319772) — completed; well-tolerated; PK profile supports progression
• Broad spectrum: active against yellow fever, Rift Valley fever, Marburg, filoviruses

Brincidofovir (CMX001)

• Lipid-conjugated prodrug of cidofovir; primarily a DNA virus drug (CMV, adenovirus)
• In vitro activity against EBOV reported; used compassionately in 2 patients during 2014 outbreak (Thomas Eric Duncan, Dallas); outcome inconclusive
• Phase II trial halted due to adverse effects and lack of demonstrated efficacy; withdrawn from EBOV development
• Mechanism of action against RNA viruses incompletely understood — likely off-target effect

Lamivudine (3TC)

• Well-established nucleoside reverse transcriptase inhibitor used in HIV/HBV therapy
• Anecdotal reports of benefit during the 2014 Liberia outbreak; case series suggested improved survival
• No controlled evidence: randomized trial data absent; insufficient evidence to recommend; likely the observed benefit was confounded by supportive care improvements
• Mechanism against EBOV RdRp not established; EBOV encodes an RNA polymerase, not a reverse transcriptase

Summary Table — Replication Inhibitors

Viral budding — the final step of EBOV egress — depends on the VP40 matrix protein hijacking host cell machinery. VP40 contains a PPXY motif that recruits the Nedd4 E3 ubiquitin ligase and Tsg101 (an ESCRT component). Additionally, VP40 interacts with host Abl-family tyrosine kinases (c-Abl1, Arg/Abl2), making these kinases druggable targets.

• Imatinib: BCR-ABL/c-Kit/PDGFR inhibitor approved for CML; inhibits c-Abl1 which is required for efficient VP40 budding — reduces EBOV VP40 VLP release by ~80% in vitro
• Nilotinib: 2nd-generation BCR-ABL inhibitor; more potent Abl kinase inhibitor; similar anti-EBOV budding activity; better selectivity profile
• Both drugs are FDA-approved and extensively characterized for safety in oncology — immediate repurposing candidates
• In vivo studies limited at time of publication; mechanistic evidence strong; combination with entry/replication inhibitors proposed for synergistic cocktail approach
• Also block Feline Leukemia Virus budding via same Abl mechanism — cross-validation of mechanism

The rationale for multi-target cocktails: combining an entry inhibitor (e.g., tetrandrine or ZMapp) + a replication inhibitor (remdesivir) + a budding inhibitor (imatinib) could theoretically block three independent stages of the viral life cycle, reducing the probability of escape and improving efficacy at lower individual doses.

EBOV actively suppresses innate immune responses through two viral proteins that counteract the interferon (IFN) pathway — VP35 and VP24. These proteins are essential virulence factors and represent high-value drug targets.

VP35 — IFN-β Transcription Blocker

• VP35 blocks activation of IRF-3 and IRF-7 (IFN regulatory factors), preventing IFN-β gene transcription after viral dsRNA sensing by RIG-I/MDA5
• VP35 dsRNA-binding domain: small molecules targeting the IID (interferon inhibitory domain) of VP35 have been identified via virtual screening
• Compounds disrupting VP35–dsRNA interaction restore IFN-β production in cell-based models
• Peptides derived from IRF-3/IRF-7 interaction surfaces competitively inhibit VP35 binding

VP24 — STAT1 Nuclear Transport Blocker

• VP24 binds karyopherin-α (importin-α) family proteins, blocking nuclear import of phosphorylated STAT1 — preventing IFN-α/β/γ signaling
• Small molecules disrupting the VP24–karyopherin-α5 interaction restore JAK-STAT signaling in infected cells
• Structural studies show a unique binding pocket on VP24 — druggable with high specificity

Restoring the host's innate immune response by blocking VP35 and/or VP24 represents a "host-directed" antiviral strategy — theoretically resistant to viral escape mutations since it acts on host pathways, not viral enzymes.

• Remdesivir is the most promising single agent: 100% NHP survival and a 3-day post-infection treatment window make it the lead candidate — later validated by its COVID-19 FDA approval
• Combination therapy is the goal: Entry + replication + budding inhibitors together provide multi-stage coverage and reduce escape probability
• ZMapp/mAb cocktails show greatest clinical translation: 100% NHP survival; compassionate use human data; PALM trial showed ZMapp performs worse than mAb114 and REGN-EB3 (post-2018 data)
• Drug repurposing accelerates timelines: Toremifene, clomiphene, imatinib, favipiravir all have known safety profiles, enabling faster phase I progression
• VP35/VP24 inhibitors represent host-directed therapy: Blocking viral IFN antagonism allows the host to fight back — less susceptible to viral resistance
• Early treatment is critical: All antiviral agents show declining efficacy as viral load rises — the therapeutic window is narrow (typically < 3–5 days post-infection for maximal benefit)